Skip to main content
MedicHelpLine
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALGeneric

NALOXEGOL

NALOXEGOL

Standard Dose
12.5MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: None (Tentative Approval)
Summary

Approval overview NALOXEGOL is listed in Drugs@FDA under application 212625 (ANDA).

Review priority: STANDARD Marketing status: None (Tentative Approval) Active ingredient NALOXEGOL Form and strength TABLET;ORAL - 12.5MG Sponsor MSN LABS PVT LTD Submission history Latest submission status date: 2021-02-24 00:00:00.

Structured Monograph

Clinical summary

Approval overview NALOXEGOL is listed in Drugs@FDA under application 212625 (ANDA). Review priority: STANDARD Marketing status: None (Tentative Approval) Active ingredient NALOXEGOL Form and strength TABLET;ORAL - 12.5MG Sponsor MSN LABS PVT LTD Submission history Latest submission status date: 2021-02-24 00:00:00. Submission type: ORIG.

Monitoring

  • Marketing status: None (Tentative Approval)
  • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.